4.8 Article

IGF-1 degradation by mouse mast cell protease 4 promotes cell death and adverse cardiac remodeling days after a myocardial infarction

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1603127113

Keywords

insulin-like growth factor-1; chymase; mouse mast cell protease 4; ischemia-reperfusion injury; cardioprotection

Funding

  1. Department of Medicine, Emory University
  2. Carlyle Fraser Heart Center, Emory University Hospital Midtown grant
  3. NIH [HL079040, HL127726, HL098481, T32HL007745, HL092141, HL093579, HL094373, HL113452]
  4. American Heart Association [13SDG16460006]
  5. Swedish Research Council
  6. Foundation Leducq
  7. National Health and Medical Research Council of Australia [573732]

Ask authors/readers for more resources

Heart disease is a leading cause of death in adults. Here, we show that a few days after coronary artery ligation and reperfusion, the ischemia-injured heart elaborates the cardioprotective polypeptide, insulin-like growth factor-1 (IGF-1), which activates IGF-1 receptor prosurvival signaling and improves cardiac left ventricular systolic function. However, this signaling is antagonized by the chymase, mouse mast cell protease 4 (MMCP-4), which degrades IGF-1. We found that deletion of the gene encoding MMCP-4 (Mcpt4), markedly reduced late, but not early, infarct size by suppressing IGF-1 degradation and, consequently, diminished cardiac dysfunction and adverse structural remodeling. Our findings represent the first demonstration to our knowledge of tissue IGF-1 regulation through proteolytic degradation and suggest that chymase inhibition may be a viable therapeutic approach to enhance late cardioprotection in post-ischemic heart disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available